Literature DB >> 18006267

Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour.

G Mentha1, P Majno, S Terraz, L Rubbia-Brandt, P Gervaz, A Andres, A S Allal, Ph Morel, A D Roth.   

Abstract

The review summarises the contributions of chemotherapy, interventional radiology and surgery to the improved survival observed in patients with colorectal liver metastases. The rationale in favour of modern neoadjuvant chemotherapy regimens, of pro-generative manoeuvres to increase the volume of the future remnant liver, and of resection techniques that preserve its function is discussed. For advanced synchronous colorectal metastases, the arguments in favour of a reversed approach with systemic chemotherapy, liver surgery and colon surgery in that order, as opposed to the traditional approach of colon surgery first, or to a simultaneous liver and large bowel resection, are presented.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006267     DOI: 10.1016/j.ejso.2007.09.016

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  25 in total

Review 1.  The surgical treatment of patients with colorectal cancer and liver metastases in the setting of the "liver first" approach.

Authors:  Leonardo Patrlj; Mario Kopljar; Robert Kliček; Masa Hrelec Patrlj; Marijan Kolovrat; Mislav Rakić; Antonija Duzel
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Colorectal Cancer OncoGuia.

Authors:  Paula Manchon Walsh; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

3.  The case for neo-adjuvant chemotherapy. For.

Authors:  Hassan Z Malik
Journal:  Ann R Coll Surg Engl       Date:  2008-09       Impact factor: 1.891

4.  Radiofrequency ablation of small liver malignancies under magnetic resonance guidance: progress in targeting and preliminary observations with temperature monitoring.

Authors:  Sylvain Terraz; Alexandru Cernicanu; Matthieu Lepetit-Coiffé; Magalie Viallon; Rares Salomir; Gilles Mentha; Christoph D Becker
Journal:  Eur Radiol       Date:  2009-09-16       Impact factor: 5.315

Review 5.  Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.

Authors:  Jianmin Xu; Xinyu Qin; Jianping Wang; Suzhan Zhang; Yunshi Zhong; Li Ren; Ye Wei; Shaochong Zeng; Deseng Wan; Shu Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-28       Impact factor: 4.553

6.  Treatment strategies for rectal cancer with synchronous liver metastases: surgical and oncological outcomes with propensity-score analysis.

Authors:  H Salvador-Rosés; S López-Ben; P Planellas; E Canals; M Casellas-Robert; R Farrés; E Ramos; A Codina-Cazador; J Figueras
Journal:  Clin Transl Oncol       Date:  2017-07-13       Impact factor: 3.405

7.  Minimally invasive sequential treatment of synchronous colorectal liver metastases by laparoscopic colectomy and robotic right hepatectomy.

Authors:  Pier Cristoforo Giulianotti; Alessandro Giacomoni; Andrea Coratti; Pietro Addeo; Francesco Maria Bianco
Journal:  Int J Colorectal Dis       Date:  2010-07-10       Impact factor: 2.571

Review 8.  Surgery for Colorectal Cancer - Trends, Developments, and Future Perspectives.

Authors:  Markus Rentsch; Tobias Schiergens; Andrej Khandoga; Jens Werner
Journal:  Visc Med       Date:  2016-06-13

Review 9.  Simultaneous laparoscopic resection of primary colorectal cancer and associated liver metastases: a systematic review.

Authors:  R M Lupinacci; W Andraus; L B De Paiva Haddad; L A Carneiro D' Albuquerque; P Herman
Journal:  Tech Coloproctol       Date:  2013-09-21       Impact factor: 3.781

10.  Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first.

Authors:  C Lim; A Doussot; M Osseis; F Esposito; C Salloum; J Calderaro; C Tournigand; D Azoulay
Journal:  Clin Transl Oncol       Date:  2018-03-28       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.